title: Can metformin or rosiglitazone reduce metabolic side effects associated with atypical antipsychotics?
authors.affiliation: Veterans Affairs Medical Center, Iowa City, Iowa, USA. audrey.housel@gmail.com
authors.forename: Audrey K
authors.initials: AK
authors.lastname: Housel
authors.forename: Nancee
authors.initials: N
authors.lastname: Waterbury
authors.forename: Tami R
authors.initials: TR
authors.lastname: Argo
mesh_terms: D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D024821:Metabolic Syndrome / Q000139:chemically induced / Q000451:nursing* / Q000517:prevention & control*; D008687:Metformin / Q000008:administration & dosage*; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D000077154:Rosiglitazone; D012559:Schizophrenia / Q000188:drug therapy*; D045162:Thiazolidinediones / Q000008:administration & dosage*; D015430:Weight Gain / Q000187:drug effects
chemical_list: D014150:Antipsychotic Agents; D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D008687:Metformin